ArticleAesthetic plastic surgery2025
Evaluation of Safety and Efficacy of Polycaprolactone-Based Fillers Combined with Glucocorticoid in Dermal Fillers: A Preclinical Investigation.
Article in Aesthetic plastic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolycaprolactone (PCL) fillers are widely used for facial rejuvenation due to their biodegradability and collagen-stimulating effects. However, PCL injections can trigger inflammation, leading to nodules and swelling. This study evaluated whether co-administration of dexamethasone and triamcinolone (PCL+D+T) mitigates inflammation while preserving collagen formation.
methodsCytotoxicity and apoptosis of PCL+D+T were assessed in fibroblast cells using MTT and Annexin V-FITC/PI assays. Sprague-Dawley rats received PCL injections alone or with corticosteroids. Local inflammation was analyzed via flow cytometry (CD86/CD206) and ELISA (CXCL-1, IL-1β, IL-10, TNF-α). Histology and transmission electron microscopy (TEM) evaluated collagen deposition and fiber structure.
resultsPCL injection increased pro-inflammatory cytokines and M1 macrophages, indicating acute inflammation. Co-treatment with dexamethasone and triamcinolone reduced inflammatory markers without impairing collagen deposition, as evidenced by similar dermal thickness, collagen area fraction, and fiber diameter across groups.
conclusionsDexamethasone and triamcinolone effectively suppress PCL-induced acute inflammation while maintaining collagen-stimulating properties. This approach may enhance PCL filler safety and efficacy, warranting further clinical investigation. NO LEVEL ASSIGNED: This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
40826293What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.